Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes
OBJECTIVE:--Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes. RESEARCH DESIGN A...
Saved in:
| Published in | Diabetes care Vol. 29; no. 8; pp. 1826 - 1832 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Alexandria, VA
American Diabetes Association
01.08.2006
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | OBJECTIVE:--Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS--Thirty-seven subjects with type 2 diabetes were evaluated. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for 3 months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1,000 μg Cr as CrPic (n = 17) for 6 months. Body composition, insulin sensitivity, and glycemic control were determined at baseline, end of the 3-month single-blind placebo phase, and end of study. RESULTS:--Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight (2.2 kg, P < 0.001 vs. 0.9 kg, P = 0.11), percent body fat (1.17%, P < 0.001 vs. 0.12%, P = 0.7), and total abdominal fat (32.5 cm², P < 0.05 vs. 12.2 cm², P < 0.10) from baseline. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass (28.8, P < 0.05 vs. 15.9, P = 0.4), GHb (-1.16%, P < 0.005 vs. -0.4%, P = 0.3), and free fatty acids (-0.2 mmol/l, P < 0.001 vs. -0.12 mmol/l, P < 0.03) as opposed to sulfonylurea/placebo. CONCLUSIONS:--This study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group. |
|---|---|
| AbstractList | Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes. Thirty-seven subjects with type 2 diabetes were evaluated. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for 3 months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1,000 µg Cr as CrPic (n = 17) for 6 months. Body composition, insulin sensitivity, and glycemic control were determined at baseline, end of the 3-month single-blind placebo phase, and end of study. Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight (2.2 kg, P < 0.001 vs. 0.9 kg, P = 0.11), percent body fat (1.17%, P < 0.001 vs. 0.12%, P = 0.7), and total abdominal fat (32.5 cm^sup 2^, P < 0.05 vs. 12.2 cm^sup 2^, P < 0.10) from baseline. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass (28.8, P < 0.05 vs. 15.9, P = 0.4), GHb (-1.16%, P < 0.005 vs. -0.4%, P = 0.3), and free fatty acids (-0.2 mmol/l, P < 0.001 vs. -0.12 mmol/l, P < 0.03) as opposed to sulfonylurea/placebo. This study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group. OBJECTIVE:--Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS--Thirty-seven subjects with type 2 diabetes were evaluated. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for 3 months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1,000 μg Cr as CrPic (n = 17) for 6 months. Body composition, insulin sensitivity, and glycemic control were determined at baseline, end of the 3-month single-blind placebo phase, and end of study. RESULTS:--Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight (2.2 kg, P < 0.001 vs. 0.9 kg, P = 0.11), percent body fat (1.17%, P < 0.001 vs. 0.12%, P = 0.7), and total abdominal fat (32.5 cm², P < 0.05 vs. 12.2 cm², P < 0.10) from baseline. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass (28.8, P < 0.05 vs. 15.9, P = 0.4), GHb (-1.16%, P < 0.005 vs. -0.4%, P = 0.3), and free fatty acids (-0.2 mmol/l, P < 0.001 vs. -0.12 mmol/l, P < 0.03) as opposed to sulfonylurea/placebo. CONCLUSIONS:--This study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group. Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes.OBJECTIVEChromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes.Thirty-seven subjects with type 2 diabetes were evaluated. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for 3 months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1,000 microg Cr as CrPic (n = 17) for 6 months. Body composition, insulin sensitivity, and glycemic control were determined at baseline, end of the 3-month single-blind placebo phase, and end of study.RESEARCH DESIGN AND METHODSThirty-seven subjects with type 2 diabetes were evaluated. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for 3 months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1,000 microg Cr as CrPic (n = 17) for 6 months. Body composition, insulin sensitivity, and glycemic control were determined at baseline, end of the 3-month single-blind placebo phase, and end of study.Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight (2.2 kg, P < 0.001 vs. 0.9 kg, P = 0.11), percent body fat (1.17%, P < 0.001 vs. 0.12%, P = 0.7), and total abdominal fat (32.5 cm(2), P < 0.05 vs. 12.2 cm(2), P < 0.10) from baseline. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass (28.8, P < 0.05 vs. 15.9, P = 0.4), GHb (-1.16%, P < 0.005 vs. -0.4%, P = 0.3), and free fatty acids (-0.2 mmol/l, P < 0.001 vs. -0.12 mmol/l, P < 0.03) as opposed to sulfonylurea/placebo.RESULTSSubjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight (2.2 kg, P < 0.001 vs. 0.9 kg, P = 0.11), percent body fat (1.17%, P < 0.001 vs. 0.12%, P = 0.7), and total abdominal fat (32.5 cm(2), P < 0.05 vs. 12.2 cm(2), P < 0.10) from baseline. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass (28.8, P < 0.05 vs. 15.9, P = 0.4), GHb (-1.16%, P < 0.005 vs. -0.4%, P = 0.3), and free fatty acids (-0.2 mmol/l, P < 0.001 vs. -0.12 mmol/l, P < 0.03) as opposed to sulfonylurea/placebo.This study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group.CONCLUSIONSThis study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group. OBJECTIVE—Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS—Thirty-seven subjects with type 2 diabetes were evaluated. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for 3 months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1,000 μg Cr as CrPic (n = 17) for 6 months. Body composition, insulin sensitivity, and glycemic control were determined at baseline, end of the 3-month single-blind placebo phase, and end of study. RESULTS—Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight (2.2 kg, P < 0.001 vs. 0.9 kg, P = 0.11), percent body fat (1.17%, P < 0.001 vs. 0.12%, P = 0.7), and total abdominal fat (32.5 cm2, P < 0.05 vs. 12.2 cm2, P < 0.10) from baseline. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass (28.8, P < 0.05 vs. 15.9, P = 0.4), GHb (−1.16%, P < 0.005 vs. −0.4%, P = 0.3), and free fatty acids (−0.2 mmol/l, P < 0.001 vs. −0.12 mmol/l, P < 0.03) as opposed to sulfonylurea/placebo. CONCLUSIONS—This study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group. Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes Julie Martin , MS, RD 1 , Zhong Q. Wang , MD 2 , Xian H. Zhang , BS 2 , Deborah Wachtel , NP, MPH 1 , Julia Volaufova , PHD 3 , Dwight E. Matthews , PHD 1 and William T. Cefalu , MD 2 1 Division of Endocrinology and Metabolism, University of Vermont, Burlington, Vermont 2 Division of Nutrition and Chronic Diseases, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana 3 Biostatistics Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana Address correspondence and reprint requests to William T. Cefalu, MD, Pennington Biomedical Research Center, 6400 Perkins Rd., Baton Rouge, LA 80808. E-mail: cefaluwt{at}pbrc.edu Abstract OBJECTIVE —Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS —Thirty-seven subjects with type 2 diabetes were evaluated. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for 3 months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo ( n = 12) or the sulfonylurea plus 1,000 μg Cr as CrPic ( n = 17) for 6 months. Body composition, insulin sensitivity, and glycemic control were determined at baseline, end of the 3-month single-blind placebo phase, and end of study. RESULTS —Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight (2.2 kg, P < 0.001 vs. 0.9 kg, P = 0.11), percent body fat (1.17%, P < 0.001 vs. 0.12%, P = 0.7), and total abdominal fat (32.5 cm 2 , P < 0.05 vs. 12.2 cm 2 , P < 0.10) from baseline. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass (28.8, P < 0.05 vs. 15.9, P = 0.4), GHb (−1.16%, P < 0.005 vs. −0.4%, P = 0.3), and free fatty acids (−0.2 mmol/l, P < 0.001 vs. −0.12 mmol/l, P < 0.03) as opposed to sulfonylurea/placebo. CONCLUSIONS —This study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group. AUC, area under the curve AUC-B, glucose AUC from the fasting glucose at time 0 CrPic, chromium picolinate DEXA, dual-energy X-ray absorptiometry FFA, free fatty acid GITS, gastrointestinal therapeutic system OGTT, oral glucose tolerance test Footnotes A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Accepted April 25, 2006. Received January 31, 2006. DIABETES CARE Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes. Thirty-seven subjects with type 2 diabetes were evaluated. After baseline, subjects were placed on a sulfonylurea (glipizide gastrointestinal therapeutic system 5 mg/day) with placebo for 3 months. Subjects were then randomized in a double-blind fashion to receive either the sulfonylurea plus placebo (n = 12) or the sulfonylurea plus 1,000 microg Cr as CrPic (n = 17) for 6 months. Body composition, insulin sensitivity, and glycemic control were determined at baseline, end of the 3-month single-blind placebo phase, and end of study. Subjects randomized to sulfonylurea/placebo, as opposed to those randomized to sulfonylurea/CrPic, had a significant increase in body weight (2.2 kg, P < 0.001 vs. 0.9 kg, P = 0.11), percent body fat (1.17%, P < 0.001 vs. 0.12%, P = 0.7), and total abdominal fat (32.5 cm(2), P < 0.05 vs. 12.2 cm(2), P < 0.10) from baseline. Subjects randomized to sulfonylurea/CrPic had significant improvements in insulin sensitivity corrected for fat-free mass (28.8, P < 0.05 vs. 15.9, P = 0.4), GHb (-1.16%, P < 0.005 vs. -0.4%, P = 0.3), and free fatty acids (-0.2 mmol/l, P < 0.001 vs. -0.12 mmol/l, P < 0.03) as opposed to sulfonylurea/placebo. This study demonstrates that CrPic supplementation in subjects with type 2 diabetes who are taking sulfonylurea agents significantly improves insulin sensitivity and glucose control. Further, CrPic supplementation significantly attenuated body weight gain and visceral fat accumulation compared with the placebo group. |
| Audience | Professional |
| Author | Zhang, Xian H Wachtel, Deborah Cefalu, William T Matthews, Dwight E Volaufova, Julia Wang, Zhong Q Martin, Julie |
| Author_xml | – sequence: 1 fullname: Martin, Julie – sequence: 2 fullname: Wang, Zhong Q – sequence: 3 fullname: Zhang, Xian H – sequence: 4 fullname: Wachtel, Deborah – sequence: 5 fullname: Volaufova, Julia – sequence: 6 fullname: Matthews, Dwight E – sequence: 7 fullname: Cefalu, William T |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18002007$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16873787$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl1rFDEUhgep2G31wj-gQVBQmDZfM8lcrqvWhYLCtvQyZDJndlNmMtsko-ytv9wMuyqUBclFPs5zXt5w3rPsxA0OsuwlwReUMXHZGFzmmBb8STYjFSvyouDyJJthwqu8qCp6mp2FcI8x5lzKZ9kpKaVgQopZ9mux8UNvxx59t2borNMR0GrcbjvowUUd7eDQPEZwY6oE9HFodugO7HoT0ZW2DmnXoKUzHnRI5aULYxJBK3DBRvvDxh2armN9DyYGdGfjBt3stoAo-mR1DUnzefa01V2AF4f9PLv98vlm8TW__na1XMyvc1NwGvOClLSmTGCsMa9ZBTXjdSvqxnAhOBZEGMwKUTMJQmpd0VTTpGqgEbpqhWHn2bu97tYPDyOEqHobDHSddjCMQZWylAxj-V-QC8IpLqsEvnkE3g-jd-kTilKGC1rJCcr30Fp3oKxrh-i1WYMDr7s0x9am5zkpJkHOeeIvjvBpNdCnER1reHVwMdY9NGrrba_9Tv0ZcgLeHgAdjO5ar52x4R8nMaYYT9zlnjN-CMFDq4zdJyA5sJ0iWE1xU1Pc1BS31PH-Ucdf0SPshz27SeH5aT2o5hCA6WB0eqCVkskOLRP8eg-3elB67ZPd2xXFhGGCK0LSkH4D4t7rMg |
| CODEN | DICAD2 |
| CitedBy_id | crossref_primary_10_1016_j_nut_2010_04_005 crossref_primary_10_1016_j_metabol_2009_09_023 crossref_primary_10_7759_cureus_63744 crossref_primary_10_1007_s12272_022_01374_6 crossref_primary_10_1016_j_jnutbio_2011_05_004 crossref_primary_10_1016_S1957_2557_07_91993_8 crossref_primary_10_1016_j_jnutbio_2008_09_006 crossref_primary_10_1016_j_jtemb_2015_05_006 crossref_primary_10_1007_s10787_019_00681_7 crossref_primary_10_1155_2014_862473 crossref_primary_10_1080_07315724_2013_816598 crossref_primary_10_3402_fnr_v60_30298 crossref_primary_10_1186_s12970_020_00367_4 crossref_primary_10_4103_ijpvm_IJPVM_137_18 crossref_primary_10_1016_j_jcjd_2013_01_029 crossref_primary_10_1016_j_jtemb_2023_127338 crossref_primary_10_2146_ajhp090109 crossref_primary_10_1080_13543784_2019_1692813 crossref_primary_10_1007_s10534_008_9165_4 crossref_primary_10_3390_ijms21072612 crossref_primary_10_1002_14651858_CD012327 crossref_primary_10_1111_obr_12026 crossref_primary_10_1007_s12011_009_8531_6 crossref_primary_10_1016_j_bioorg_2019_102942 crossref_primary_10_1016_j_ijheh_2024_114323 crossref_primary_10_1089_act_2006_13105 crossref_primary_10_1093_mtomcs_mfac082 crossref_primary_10_2337_dc06_1852 crossref_primary_10_1007_s11892_011_0184_0 crossref_primary_10_1038_s41598_023_35338_7 crossref_primary_10_3390_nu15173782 crossref_primary_10_1177_0897190009332658 crossref_primary_10_1007_s11356_023_26700_3 crossref_primary_10_1111_j_2042_3306_2010_00302_x crossref_primary_10_1186_1472_6823_12_31 crossref_primary_10_1002_adma_202407425 crossref_primary_10_1007_s12013_011_9326_x crossref_primary_10_1074_mcp_M700198_MCP200 crossref_primary_10_1007_s12011_009_8557_9 crossref_primary_10_3390_antiox13010040 crossref_primary_10_1002_dmrr_755 crossref_primary_10_1016_j_microc_2019_02_029 crossref_primary_10_3390_toxics11030272 crossref_primary_10_1089_ars_2007_1577 crossref_primary_10_1007_s10787_022_01025_8 crossref_primary_10_1016_j_jnutbio_2010_10_001 crossref_primary_10_1038_oby_2008_217 crossref_primary_10_3132_dvdr_2007_002 crossref_primary_10_2174_1872211313666191010093148 crossref_primary_10_1002_pdi_1908 crossref_primary_10_1016_j_mehy_2015_06_005 crossref_primary_10_1016_j_jpsychores_2013_03_092 crossref_primary_10_1128_JB_00077_19 crossref_primary_10_1186_1758_5996_2_70 crossref_primary_10_1002_dmrr_740 crossref_primary_10_1007_s11802_011_1860_z crossref_primary_10_1039_C6NR00398B crossref_primary_10_1016_j_jtemb_2021_126741 crossref_primary_10_1016_j_fct_2012_02_012 crossref_primary_10_1089_met_2008_0048 crossref_primary_10_1177_0884533608318676 crossref_primary_10_1089_dia_2006_8_677 crossref_primary_10_1080_19390211_2016_1207124 crossref_primary_10_15421_021931 crossref_primary_10_1007_s12011_021_02693_3 crossref_primary_10_1007_s12011_009_8417_7 crossref_primary_10_1093_nutrit_nuw011 crossref_primary_10_7762_cnr_2020_9_2_97 crossref_primary_10_1111_1750_3841_14138 crossref_primary_10_3390_molecules28010249 crossref_primary_10_1093_jn_138_10_1846 crossref_primary_10_1016_j_jcjd_2017_10_023 crossref_primary_10_1186_s40580_019_0206_1 crossref_primary_10_1007_s12011_017_1014_2 crossref_primary_10_2337_dc06_2192 crossref_primary_10_3945_jn_115_214569 crossref_primary_10_1016_S1155_1941_09_49501_5 crossref_primary_10_1016_j_tiv_2007_12_007 crossref_primary_10_3390_antiox13111283 crossref_primary_10_1016_j_nupar_2017_09_002 crossref_primary_10_1007_s12011_019_01783_7 crossref_primary_10_3109_19390211_2013_830678 crossref_primary_10_3390_ani10091685 crossref_primary_10_1016_j_ctim_2020_102540 crossref_primary_10_1016_j_jtemb_2016_04_002 crossref_primary_10_29038_2617_4723_2015_313_161_166 crossref_primary_10_1155_2014_717219 crossref_primary_10_2217_nnm_2016_0119 crossref_primary_10_3390_biom10030398 crossref_primary_10_1016_j_molstruc_2019_04_015 crossref_primary_10_1002_14651858_CD012327_pub2 crossref_primary_10_1016_j_fct_2010_07_008 crossref_primary_10_1007_s12011_010_8917_5 crossref_primary_10_1111_jcpt_12147 crossref_primary_10_1002_biof_194 crossref_primary_10_3390_antiox12081572 crossref_primary_10_1186_s12937_020_00625_w crossref_primary_10_1016_j_pop_2010_02_008 crossref_primary_10_1002_mnfr_201700438 crossref_primary_10_1371_journal_pone_0281019 crossref_primary_10_1111_j_1753_0407_2012_00211_x crossref_primary_10_1016_j_freeradbiomed_2007_06_029 crossref_primary_10_2337_dc06_1719 crossref_primary_10_3164_jcbn_2008064 crossref_primary_10_1111_j_1475_1313_2008_00595_x crossref_primary_10_7554_eLife_02245 crossref_primary_10_1038_oby_2007_322 crossref_primary_10_1016_j_freeradbiomed_2007_05_019 crossref_primary_10_1089_acm_2009_0286 crossref_primary_10_1016_j_jada_2007_12_007 crossref_primary_10_1097_MED_0b013e3280d5f7e9 crossref_primary_10_1097_TIN_0b013e31828d7bb1 crossref_primary_10_15436_2376_0494_15_016 crossref_primary_10_1016_j_foodchem_2011_07_113 crossref_primary_10_1007_s11892_010_0097_3 crossref_primary_10_1016_j_jcjd_2013_07_012 crossref_primary_10_1039_c3fo30317a crossref_primary_10_1038_ncpendmet0311 crossref_primary_10_2337_dc06_0996 crossref_primary_10_31893_jabb_20025 crossref_primary_10_1007_s12349_009_0065_0 crossref_primary_10_1371_journal_pone_0138646 crossref_primary_10_4158_EP10131_OR crossref_primary_10_1002_biof_1253 crossref_primary_10_1017_S0029665108006010 crossref_primary_10_1007_s12011_023_04010_6 crossref_primary_10_1016_j_metabol_2007_07_007 crossref_primary_10_1177_0884533609342436 crossref_primary_10_1016_j_jtemb_2011_01_001 crossref_primary_10_1016_S2095_4964_14_60020_0 crossref_primary_10_1007_s12011_022_03474_2 crossref_primary_10_1155_2016_9261259 crossref_primary_10_1002_iub_84 crossref_primary_10_1089_dia_2007_0292 crossref_primary_10_1111_j_1559_4564_2007_06366_x |
| Cites_doi | 10.1079/PNS2003256 10.1123/ijsnem.12.2.125 10.1210/jcem.83.11.5225 10.1016/S0011-393X(96)80080-4 10.1093/ajcn/63.6.954 10.1016/j.ecl.2004.12.002 10.2337/diacare.25.12.2123 10.1093/ajcn/41.6.1177 10.1097/00005768-199601000-00025 10.1152/ajpendo.1979.237.3.E214 10.2337/diabetes.46.11.1786 10.1093/clinchem/40.7.1317 10.1093/jn/133.6.1992S 10.2337/diabetes.29.11.919 10.1124/jpet.105.085712 10.2337/diacare.29.s1.06.s4 10.1136/bmj.310.6972.83 10.1111/j.1753-4887.1999.tb06909.x 10.2337/diacare.28.3.712 10.1016/S0011-393X(98)85040-6 10.1002/(SICI)1098-2299(199805)44:1<1::AID-DDR1>3.0.CO;2-L 10.1002/(SICI)1520-670X(1999)12:2<71::AID-JTRA4>3.0.CO;2-8 10.1123/ijsn.4.2.142 10.1079/BJN19920078 10.1016/0024-3205(88)90286-X 10.2337/diacare.28.7.1841-a 10.2337/diacare.27.11.2741 10.1152/ajpendo.2001.281.1.E113 10.1016/S0026-0495(96)90049-9 10.1046/j.1463-1326.1999.00055.x 10.1093/gerona/55.5.M260 10.2165/00024677-200302010-00004 10.2337/diacare.29.03.06.dc05-1453 10.1016/0026-0495(81)90074-3 |
| ContentType | Journal Article |
| Copyright | 2006 INIST-CNRS COPYRIGHT 2006 American Diabetes Association Copyright American Diabetes Association Aug 2006 |
| Copyright_xml | – notice: 2006 INIST-CNRS – notice: COPYRIGHT 2006 American Diabetes Association – notice: Copyright American Diabetes Association Aug 2006 |
| DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7X2 7X7 7XB 88E 88I 8AF 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AN0 ATCPS AZQEC BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K9- K9. KB0 M0K M0R M0S M0T M1P M2O M2P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U S0X 7S9 L.6 7X8 |
| DOI | 10.2337/dc06-0254 |
| DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database Agricultural & Environmental Science Collection ProQuest Central Essentials eLibrary ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Agricultural Science Database Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database ProQuest Research Library Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic SIRS Editorial AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Research Library Prep ProQuest Central Student ProQuest Central Essentials elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Health Research Premium Collection Natural Science Collection Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Family Health ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Agricultural & Environmental Science Collection ProQuest Research Library ProQuest Public Health ProQuest Central Basic ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library ProQuest Central (Alumni) AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database AGRICOLA MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1935-5548 |
| EndPage | 1832 |
| ExternalDocumentID | 1124917561 A150693444 16873787 18002007 10_2337_dc06_0254 diacare_29_8_1826 US201301091108 |
| Genre | Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: NCRR NIH HHS grantid: M01RR00109 – fundername: NIDDK NIH HHS grantid: R01 DK060126 – fundername: NIDDK NIH HHS grantid: R55 DK060126 |
| GroupedDBID | --- -ET ..I .55 .GJ .XZ 08P 0R~ 18M 29F 2WC 3O- 4.4 41~ 53G 5GY 5RE 5RS 5VS 6PF 7RV 7X2 7X7 88E 88I 8AF 8AO 8C1 8F7 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AAIKC AAKAS AAMNW AAQOH AAQQT AAWTL AAYEP AAYJJ ABOCM ABPPZ ABUWG ACGFO ACGOD ADBBV ADZCM AEGXH AENEX AERZD AFFNX AFKRA AFOSN AFRAH AHMBA AI. AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI ATCPS AZQEC BAWUL BCR BCU BEC BENPR BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BTFSW BVXVI C1A CCPQU CS3 DIK DU5 DWQXO E3Z EBS EDB EJD EMOBN EX3 F5P FBQ FYUFA GNUQQ GUQSH GX1 H13 HCIFZ HMCUK HZ~ IAG IAO IEA IHR INH INR IOF IPO ITC J5H K9- KQ8 L7B M0K M0R M0T M1P M2O M2P M2Q M5~ N4W NAPCQ O5R O5S O9- OK1 OVD P2P PCD PEA PHGZT PQQKQ PROAC PSQYO Q2X RHI S0X SJFOW SV3 TDI TEORI TR2 TWZ UKHRP VH1 VVN W8F WH7 WHG WOQ WOW X7M YHG YOC ZCG ZGI ZXP ~KM - 0R 1AW 3V. 55 AASXA ABFLS ABPTK ACJLH ACVYA ADACO ADBIT AFDAS BBAFP ET GJ HZ IGG KM M5 MBDVC O0- PADUT PQEST PQUKI PRINS RHF XZ ZA5 AAFWJ AAYXX CITATION PHGZM IQODW PJZUB PPXIY CGR CUY CVF ECM EIF NPM PMFND 7XB 8FK K9. PKEHL Q9U 7S9 L.6 7X8 |
| ID | FETCH-LOGICAL-c542t-5162b23700a04b39eb34bf7bdc47740717c0357b38e78aa92f7ba19ded7a9f7c3 |
| IEDL.DBID | 7X7 |
| ISSN | 0149-5992 |
| IngestDate | Thu Jul 10 18:54:14 EDT 2025 Fri Jul 11 08:11:46 EDT 2025 Sat Jul 26 02:30:28 EDT 2025 Fri Jun 13 00:45:39 EDT 2025 Tue Jun 10 21:38:49 EDT 2025 Mon Jul 21 06:06:36 EDT 2025 Mon Jul 21 09:14:58 EDT 2025 Thu Apr 24 22:59:52 EDT 2025 Tue Jul 01 03:45:09 EDT 2025 Fri Jan 15 19:48:11 EST 2021 Thu Apr 03 09:43:48 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Endocrinopathy Type 2 diabetes Human Pancreatic hormone Sensitivity Body weight Chromium Metabolic diseases Supplementation Insulin Weight gain Pyridine derivatives |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c542t-5162b23700a04b39eb34bf7bdc47740717c0357b38e78aa92f7ba19ded7a9f7c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://diabetesjournals.org/care/article-pdf/29/8/1826/593598/zdc00806001826.pdf |
| PMID | 16873787 |
| PQID | 223052989 |
| PQPubID | 47715 |
| PageCount | 7 |
| ParticipantIDs | proquest_journals_223052989 pascalfrancis_primary_18002007 gale_infotracacademiconefile_A150693444 proquest_miscellaneous_68683008 crossref_citationtrail_10_2337_dc06_0254 proquest_miscellaneous_47142069 fao_agris_US201301091108 gale_infotracgeneralonefile_A150693444 crossref_primary_10_2337_dc06_0254 pubmed_primary_16873787 highwire_diabetes_diacare_29_8_1826 |
| ProviderPackageCode | RHF RHI CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2006-08-01 |
| PublicationDateYYYYMMDD | 2006-08-01 |
| PublicationDate_xml | – month: 08 year: 2006 text: 2006-08-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Alexandria, VA |
| PublicationPlace_xml | – name: Alexandria, VA – name: United States – name: Alexandria |
| PublicationTitle | Diabetes care |
| PublicationTitleAlternate | Diabetes Care |
| PublicationYear | 2006 |
| Publisher | American Diabetes Association |
| Publisher_xml | – name: American Diabetes Association |
| References | 2022031219564081400_R31 2022031219564081400_R30 2022031219564081400_R11 2022031219564081400_R33 2022031219564081400_R10 2022031219564081400_R32 2022031219564081400_R17 2022031219564081400_R39 2022031219564081400_R16 2022031219564081400_R38 2022031219564081400_R19 2022031219564081400_R18 2022031219564081400_R13 2022031219564081400_R35 2022031219564081400_R12 2022031219564081400_R34 2022031219564081400_R15 2022031219564081400_R37 2022031219564081400_R14 2022031219564081400_R36 2022031219564081400_R20 2022031219564081400_R22 2022031219564081400_R21 2022031219564081400_R9 2022031219564081400_R7 2022031219564081400_R8 2022031219564081400_R28 2022031219564081400_R27 2022031219564081400_R29 2022031219564081400_R24 2022031219564081400_R23 2022031219564081400_R26 2022031219564081400_R25 2022031219564081400_R5 2022031219564081400_R6 2022031219564081400_R3 2022031219564081400_R4 2022031219564081400_R1 2022031219564081400_R2 17130232 - Diabetes Care. 2006 Dec;29(12):2764; author reply 2764-5 |
| References_xml | – ident: 2022031219564081400_R30 doi: 10.1079/PNS2003256 – ident: 2022031219564081400_R31 – ident: 2022031219564081400_R17 doi: 10.1123/ijsnem.12.2.125 – ident: 2022031219564081400_R8 doi: 10.1210/jcem.83.11.5225 – ident: 2022031219564081400_R24 doi: 10.1016/S0011-393X(96)80080-4 – ident: 2022031219564081400_R18 doi: 10.1093/ajcn/63.6.954 – ident: 2022031219564081400_R1 doi: 10.1016/j.ecl.2004.12.002 – ident: 2022031219564081400_R15 doi: 10.2337/diacare.25.12.2123 – ident: 2022031219564081400_R32 doi: 10.1093/ajcn/41.6.1177 – ident: 2022031219564081400_R19 doi: 10.1097/00005768-199601000-00025 – ident: 2022031219564081400_R6 doi: 10.1152/ajpendo.1979.237.3.E214 – ident: 2022031219564081400_R21 doi: 10.2337/diabetes.46.11.1786 – ident: 2022031219564081400_R12 doi: 10.1093/clinchem/40.7.1317 – ident: 2022031219564081400_R14 – ident: 2022031219564081400_R3 doi: 10.1093/jn/133.6.1992S – ident: 2022031219564081400_R33 – ident: 2022031219564081400_R23 doi: 10.2337/diabetes.29.11.919 – ident: 2022031219564081400_R2 doi: 10.1124/jpet.105.085712 – ident: 2022031219564081400_R5 doi: 10.2337/diacare.29.s1.06.s4 – ident: 2022031219564081400_R28 doi: 10.1136/bmj.310.6972.83 – ident: 2022031219564081400_R36 doi: 10.1111/j.1753-4887.1999.tb06909.x – ident: 2022031219564081400_R38 doi: 10.2337/diacare.28.3.712 – ident: 2022031219564081400_R25 doi: 10.1016/S0011-393X(98)85040-6 – ident: 2022031219564081400_R13 doi: 10.1002/(SICI)1098-2299(199805)44:1<1::AID-DDR1>3.0.CO;2-L – ident: 2022031219564081400_R35 doi: 10.1002/(SICI)1520-670X(1999)12:2<71::AID-JTRA4>3.0.CO;2-8 – ident: 2022031219564081400_R34 doi: 10.1123/ijsn.4.2.142 – ident: 2022031219564081400_R20 doi: 10.1079/BJN19920078 – ident: 2022031219564081400_R26 – ident: 2022031219564081400_R29 doi: 10.1016/0024-3205(88)90286-X – ident: 2022031219564081400_R37 doi: 10.2337/diacare.28.7.1841-a – ident: 2022031219564081400_R4 doi: 10.2337/diacare.27.11.2741 – ident: 2022031219564081400_R9 doi: 10.1152/ajpendo.2001.281.1.E113 – ident: 2022031219564081400_R10 doi: 10.1016/S0026-0495(96)90049-9 – ident: 2022031219564081400_R16 doi: 10.1046/j.1463-1326.1999.00055.x – ident: 2022031219564081400_R22 doi: 10.1093/gerona/55.5.M260 – ident: 2022031219564081400_R11 – ident: 2022031219564081400_R27 doi: 10.2165/00024677-200302010-00004 – ident: 2022031219564081400_R39 doi: 10.2337/diacare.29.03.06.dc05-1453 – ident: 2022031219564081400_R7 doi: 10.1016/0026-0495(81)90074-3 – reference: 17130232 - Diabetes Care. 2006 Dec;29(12):2764; author reply 2764-5 |
| SSID | ssj0004488 |
| Score | 2.2921417 |
| Snippet | OBJECTIVE:--Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to... Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes Julie Martin , MS, RD 1 ,... OBJECTIVE—Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to... Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the... |
| SourceID | proquest gale pubmed pascalfrancis crossref highwire fao |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1826 |
| SubjectTerms | abdominal fat Adipose Tissue Adipose Tissue - drug effects Adult Aged Agents Biological and medical sciences blood glucose Chromium Chromium (Nutrient) Clinical medicine Diabetes Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - physiopathology Diabetes. Impaired glucose tolerance Diet therapy Dietary supplements Disease control drug effects drug therapy Drug Therapy, Combination Endocrine pancreas. Apud cells (diseases) Endocrinopathies Environmental health Etiopathogenesis. Screening. Investigations. Target tissue resistance Female free fatty acids gastrointestinal system glipizide glucose glycemic control Health aspects Humans Insulin Insulin - therapeutic use insulin resistance lean body mass Male Medical sciences Medical treatment Metabolism Middle Aged noninsulin-dependent diabetes mellitus Patients pharmacology Phenotype physiopathology Picolinic Acids Picolinic Acids - pharmacology therapeutic use Type 2 diabetes visceral fat weight gain Weight Gain - drug effects |
| Title | Chromium Picolinate Supplementation Attenuates Body Weight Gain and Increases Insulin Sensitivity in Subjects With Type 2 Diabetes |
| URI | http://care.diabetesjournals.org/content/29/8/1826.abstract https://www.ncbi.nlm.nih.gov/pubmed/16873787 https://www.proquest.com/docview/223052989 https://www.proquest.com/docview/47142069 https://www.proquest.com/docview/68683008 |
| Volume | 29 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZoKyEuiHdDYbEAAZeoie3E8QltS0sLalVRVt2b5UdSVqJJIcmBK7-cmTx2tVKLtIo2shU7GXv8zXj8DSFvVZ7YyHMZujSXISDiPDSZU6EXrDAM8AWL8YDzyWl6NBNf5sl8iM2ph7DKUSd2itpXDn3ku7CM4aZUpj5e_woxaRRurg4ZNDbIFjKXYUSXnMvVsUjRpZ1EIyBMlGI9sRDjXO56h4Y0S8TacrRRmGqlmke-YAyXNDV8saJPdXE7Fu3WpMMH5P4AJum0l_5DcicvH5G7J8N2-WPyF6lvrxbtFT1DgS9KAJa0y-PZx4yjUOi0AdjcIuSke5X_Qy86Zyn9bBYlNaWnoEEwcB2Kj_u4dXqOQe991gmKt61FZ05NLxbND4qGLWV0iLSpn5DZ4cH3_aNwSLoQukSwJkzilFnGZRSZSFiuwNgWtpDWOwFIEa0_F_FEWp7lMjNGMSgzsfK5l0YV0vGnZLOsynyb0NQqZbyTaYEkfbywXubSOi-LpEiLNAvIh_HbazcwkmNijJ8aLBMUk0YxaRRTQF4vq173NBw3VdoGAWpzCepRz84Zbsoi72kcQVPvUaoaZy004cxw-AA6ivxXeopEi4oLAQ95t1bzsmf_vqnim3GE6NFPjn8wYk8zpTONpltAJmuDZ9X7DqlHMiA742jSg_qo9XKwB-TVshTmPW7mmDKv2loDqBAMunJ7jTRLMx7huz_rB-mq7TSTHDT18_-2vUPu9Q50_L0gm83vNn8JCKyxk26ewTXbjydka-_g9Owb3H06_voPzjMyAw |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2TgJeEN8rg83i-yVaajtx_IBQBxstW6uJrdrejGMnoxJLB2mF9sr_w__IXZy0qrTxtrdEPsVu73z-3YfvCHmlsigNHZeBjTMZACLOApNYFTjBcsMAX7AOXnAeDOPeSHw5jU5XyN_mLgymVTY6sVLUbmLRR74NxxgGpRL14eJngE2jMLjadNDwUrGfXf4Gi6183_8E7H3N2N7u8cdeUDcVCGwk2DSIOjFLGZdhaEKRcgXGpEhzmTorAAmhdWNDHsmUJ5lMjFEMxkxHucxJo3JpOXx3lawJDpZMi6zt7A4Pvy4uYoqq0SWaHUGkFPOljBjncttZNN1ZJJYOwNXcTBaHQVOhGBM0TQk8yn1zjevRb3UK7t0jd2v4Srte3u6Tlax4QG4N6gD9Q_IHi-2ej2fn9BBFbFwAlKVV51CfpY5iQLtTAOozBLl0Z-Iu6UnlnqWfzbigpnAUdBamysNw32fK0yNMs_d9Lii-zlJ0H5X0ZDz9TtGUpozWuT3lIzK6EY48Jq1iUmTrhMapUsZZGedYFpDnqZOZTK2TeZTHeZy0ybvmv9e2roGOrTh-aLCFkE0a2aSRTW3yYk564Qt_XEW0DgzU5gwUsh4dMQwDY6XVTghTvUWuatQTMIU19XUHWChW3NJdLO2ouBDwkTdLlGe-3vhVhC8bCdGNZx4fMEdQM6UTjcZim2wuCc9i9ZVtEMo22WikSdcKq9Tz7dUmW_NR0DQYPjJFNpmVGmCMYLCU6yniJE54iL_9iRfSxdxxIjmcDU__O_cWud07Hhzog_5wf4Pc8d4uzLV8RlrTX7PsOeC_abpZ7zpKvt30Rv8HbmVsqw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbhMx1GqLVHFB7A2F1mK_jDKxPePxAaFACQ2lVaVSNTfX46VEopPCJEK98lf8He_NkihSy623Gflp7OTti98j5KXySR47LiObehmBRewjk1kVOcGCYWBfsB5ecN4_SHePxZdRMlohf9u7MFhW2crESlC7icUYeRfUGCalMtUNTVXE4c7g_cXPCAdIYaK1naZRU8iev_wN3lv5brgDqH7F2ODTt4-7UTNgILKJYNMo6aUsZ1zGsYlFzhU4liIPMndWgFWEno6NeSJznnmZGaMYrJmect5Jo4K0HL67Sm5JnvSQxeRILq5kimrkJTogUaIUq5saMc5l11l04lkillThajCThVpoexVjqaYpAVuhHrNxvR1c6cPBXXKnMWRpv6a8e2TFF_fJ-n6Tqn9A_mDb3fPx7JweIrGNCzBqaTVDtK5XR4Kg_SmY7DM0d-mHibukJ1Wgln4244KawlGQXlg0D8vDumaeHmHBfT3xguLrLMdAUklPxtPvFJ1qymhT5VM-JMc3go9HZK2YFH6D0DRXyjgr04ANAnnInfQyt06GJKQhzTrkbfvfa9t0Q8ehHD80eEWIJo1o0oimDnk-B72oW4BcBbQBCNTmDESzPj5imBDGnqu9GLZ6g1jVKDFgC2uaiw9wUOy9pfvY5FFxIeAjr5cgz-rO41cBvmgpRLcxenzAakHNlM40uo0dsrVEPIvTV15CLDtks6Um3YiuUs8ZrUO256sgczCRZAo_mZUaDBrB4CjXQ6RZmvEYf_vjmkgXe6eZ5KAlnvx3722yDuytvw4P9jbJ7TrshUWXT8na9NfMPwNDcJpvVSxHyelN8_g_WKdvew |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chromium+Picolinate+Supplementation+Attenuates+Body+Weight+Gain+and+Increases+Insulin+Sensitivity+in+Subjects+With+Type+2+Diabetes&rft.jtitle=Diabetes+care&rft.au=Julie+Martin&rft.au=Zhong+Q.+Wang&rft.au=Xian+H.+Zhang&rft.au=Deborah+Wachtel&rft.date=2006-08-01&rft.pub=American+Diabetes+Association&rft.issn=0149-5992&rft.eissn=1935-5548&rft.volume=29&rft.issue=8&rft.spage=1826&rft_id=info:doi/10.2337%2Fdc06-0254&rft_id=info%3Apmid%2F16873787&rft.externalDBID=n%2Fa&rft.externalDocID=diacare_29_8_1826 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon |